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Abstract
Ivabradine is a specific heart rate-reducing agent approved as a treatment of chronic stable angina. Its mode of action
involves a selective and specific block of HCN channels, the molecular components of sinoatrial "funny" (f)-channels.
Different studies suggest that the binding site of ivabradine is located in the inner vestibule of HCN channels, but the
molecular details of ivabradine binding are unknown. We thus sought to investigate by mutagenesis and in silico analysis
which residues of the HCN4 channel, the HCN isoform expressed in the sinoatrial node, are involved in the binding of
ivabradine. Using homology modeling, we verified the presence of an inner cavity below the channel pore and identified
residues lining the cavity; these residues were replaced with alanine (or valine) either alone or in combination, and WT and
mutant channels were expressed in HEK293 cells. Comparison of the block efficiency of mutant vs WT channels, measured
by patch-clamp, revealed that residues Y506, F509 and I510 are involved in ivabradine binding. For each mutant channel,
docking simulations correctly explain the reduced block efficiency in terms of proportionally reduced affinity for ivabradine
binding. In summary our study shows that ivabradine occupies a cavity below the channel pore, and identifies specific
residues facing this cavity that interact and stabilize the ivabradine molecule. This study provides an interpretation of known
properties of f/HCN4 channel block by ivabradine such as the ‘‘open channel block’’, the current-dependence of block and
the property of "trapping" of drug molecules in the closed configuration.
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Introduction
Cardiac f- and their neuronal relatives h-channels play a key
role in the control of heart rate and neuronal excitability. These
channels have a tetrameric composition, with single subunits
belonging to the Hyperpolarization-activated Cyclic Nucleotide-
gated (HCN) channel family. The HCN family includes 4
members (HCN1-4) that are differentially expressed in excitable
tissues [1]. Each HCN subunit is organized according to a six
transmembrane (S1–S6) structure, with an additional C-terminal
cytosolic regulatory domain involved in cyclic nucleotide binding
(CNBD) [1]. As in KcsA, Shaker, and HERG channels, also in
HCN channels four subunits assemble to form a conduction
pathway formed by the selectivity filter, a relatively large cavity
lined by hydrophobic residues and the activation gate [2–6].
As well as playing a basic role in cardiac pacemaking, HCN
channels have several important functions in neurons [7].
Increasing evidence suggests that the development of drugs
targeting HCN channels may be useful as perspective bradycardic,
anthiarrhythmic, anticonvulsant, analgesic and anaesthetic com-
pounds [8]. Ivabradine is the first member of the ‘‘heart rate-
reducing’’ family (If blocking agents) clinically approved by the
European Medicines Evaluation Agency for the treatment of
angina and heart failure. Given its clinical use, it is important to
understand the molecular details of ivabradine block of HCN4
channels, the main isoform expressed in the pacemaker region of
the heart. Some of the basic properties of the molecular interaction
between ivabradine molecules and native f/HCN channels have
been already clarified. For example it is known that drug
molecules act intracellularly [9], and that the block is strongly
state-dependent since it can only occur after channel opening [9–
11]. In a study of mHCN1 block by ZD7288, another HCN
blocking molecule interacting with pore-lining channel residues,
Shin et al. [2] have shown that blocking molecules are "trapped"
within channels in the closed state. Block of HCN4/f channels by
ivabradine also has the unusual property of being "current-
dependent", since it depends upon the flow of ions through the
pore (kick-in/kick-off mechanisms). A tentative interpretation of
this phenomenon predicts that the positively charged quaternary
N+ ion of ivabradine antagonizes Na+/K+ permeating ions in their
binding sites in the pore [9–11], but no evidence has been
provided yet to support this hypothesis.
Despite the understanding of the basic features described above,
no information is available yet on the specific interaction between
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ivabradine and the residues of the HCN4 channel and on the
molecular details of block. We therefore set out to investigate the
HCN4 channel block by ivabradine with three complementary
approaches: 1) in silico analysis through homology molecular
modeling (seeking information on the 3D structure of the channel
pore); 2) mutagenesis and electrophysiological characterization of
the interaction between ivabradine and mutated HCN4 channels;
3) in silico molecular docking, providing insight into the drug
binding mode. Our data identify some specific residues in the S6
domain lining the internal mouth of channel pore acting in concert
to bind ivabradine and provide a molecular-based explanation of
known features of block.
Materials and Methods
Homology Modeling
In the absence of the crystal structure of the hHCN4 channel,
a homology model of the pore region (S5-P-S6 region) of hHCN4
was obtained based on the Streptomyces lividans K+ channel (KcsA)
X-ray structure, both in the closed (PDB-code 1BL8; [12]) and
open forms (PDB-code 3FB7; [13]) (Fig. 1A,B). Sequence
alignment was performed by first identifying potential trans-
membrane regions of the HCN sequences spanning the S5-P-S6
region with the programs TopPread 2 (S5: V419-V439; S6: V492-
H512) [14], TMHMM v2.0 (S5:V419-M441; S6: L494-L516)
[15], and HMMTOP (S5: I418-L442; S6: V492-A515) [16].
These regions were then used to guide the sequence alignment
with the TM1-P-TM2 region of KcsA performed by CLUSTALW
[17]. While the alignment of the HCN S6/TM2 region was
readily achieved (based on the register provided by the GYG motif
in the selectivity filter SF), the alignment of the predicted HCN
S5/TM1 helix was not trivial, primarily because of the long S5/
TM1-P linker in HCN and limited amino acid conservation with
KcsA. For this reason we introduced a third sequence, from the rat
Kv1.2 channel, to provide additional information useful to search
for the proper register among KcsA, HCN4 and Kv1.2 S5/TM1.
The KcsA and Kv1.2 sequences were first structurally aligned by
superimposing their structures in the open state (PDB-codes 3FB7
and 2A79, respectively). The boundaries of S5/TM1 helix where
then defined by identifying the conservation of HCN4 A414, R417
(in the first turn of the S5/TM1 helix in both KcsA and Kv1.2),
L421, L426, and G433, thus positioning HCN4 P440 at the C-
terminus of the S5/TM1 helix, as expected for a proline residue. A
long gap was inserted between the S5/TM1 and the pore-helix in
the KcsA sequence to align the predicted S5/TM1 and S6/TM2
helices of the HCN channels with those of the template (Fig. 1B).
This alignment maximizes the overlap between TM prediction
and sequence similarity to KcsA and Kv1.2 channels.
The tetrameric channel template was reconstructed by applying
the appropriate crystallographic symmetry operations to the
crystal structures 1BL8 and 3FB7. Then, the modelling of the
tetrameric hHCN4 channel was performed by the program
Modeller9v3 [18] using the model-multichain symmetry option.
Ten models were generated and evaluated by using the discrete
optimized protein energy (DOPE) score [19]. The best model was
energy-minimized using the optimize procedure as implemented
in the Modeller9v3 program and the stereochemistry further
optimized by the stereochemical idealization procedure as
implemented in the program REFMAC [20]. The program
Procheck [21] was used to assess stereochemical quality.
Similar protein modeling was adopted for the hHCN4 mutants
Y506A, I510A, and Y506A-I510A, with the channel in the closed
form, and for the F509A mutant with the channel both in the open
and closed form.
hHCN4 Mutagenesis and Expression in HEK293 Cells
Point mutations were introduced into hHCN4 cDNA using
QuikChangeH II XL site-directed mutagenesis kit (Stratagene) and
confirmed by DNA sequencing.
Human Embryonic Kidney cells (HEK 293, Phoenix) were
cultured in Dulbecco’s MEM plus GlutaMAXTM-I supplemented
with 10% fetal bovine serum (GIBCO BRL) and antibiotics
(PenStrept, SIGMA, Italy) at 37uC in 5% CO2. Expression vectors
(pCDNA1.1) containing either the wild type (WT) or mutated
hHCN4 cDNAs and a vector with the green fluorescent protein
(pmaxGFP, Amaxa Biosystems) were co-transfected in HEK cells
using either the LipofectamineTM Reagent (Invitrogen) or the
FuGENEH HD Transfection Reagent (Roche). Cells were in-
cubated at 37uC (5% CO2) for 2–3 days to allow for a good level of
protein expression prior to electrophysiology experiments. On the
day of the experiment, cells were detached and dispersed by
trypsin and plated at a low density on a 35 mm plastic Petri dish.
The dish was then placed under the stage of an inverted
fluorescence microscope, and GFP-expressing cells were selected
for voltage-clamp analysis.
Voltage-clamp Recordings
All experiments were carried out in the whole-cell configuration
at the temperature of 3260.5uC. The recording pipettes contained
(in mM): NaCl 10, K-Aspartate 130, MgCl2 0.5, EGTA-KOH 1,
HEPES-KOH 1, ATP (Na-salt) 2, GTP (Na-salt) 0.1, phospho-
creatine 5, (pH 7.2). The control extracellular solution contained
(in mM): NaCl 140, KCl 5.4, CaCl2 1.8, MgCl2 1, D-glucose 5.5,
HEPES-NaOH 5, (pH 7.4); BaCl2 1 mM, and MnCl2 2 mM were
added to improve dissection of the HCN current. Ivabradine was
added to the extracellular solution by dissolving a stock solution
(10–50 mM) to the desired final concentration. Currents were
recorded and filtered online at a corner frequency of 1 KHz with
an Axopatch 200B amplifier, and acquired using the pClamp 10.1
software. Activation curves for HCN currents were obtained by
the following voltage protocol: from a holding potential of 225/
235 mV test voltage steps ranging from -40 to -145 mV (15 mV
interval) were applied until steady-state current activation was
attained at each potential; test steps were then followed by a pulse
to 2130 (or 2145 mV in some protocols) and by a deactivating
pulse to +10 mV. Time constants of activation (at 2140 mV) and
deactivation (at +5 mV) were obtained by fitting with a mono-
exponential function the time-dependent current traces; the initial
delay [22] was ignored.
Ivabradine block of WT hHCN4 channels was investigated by
superfusing the drug during repetitive (0.5 Hz) application of
activating (2140 mV, 0.6 s)/deactivating (+5 mV, 0.3 s) steps,
from a holding potential of 235 mV. The fractional current block
was calculated as the ratio between block-induced current
reduction and control current (at 2140 mV). For some mutant
currents this protocol was modified to account for changes in the
current kinetics as follows: for mutants Y506A, A507V, F509A,
Y506A-F509A the duration of the activating step was increased to
1 s; for mutant I510A the duration of the activating step was
shortened to 0.2 s; for mutant F509A the deactivation step
duration and the frequency of stimulation were set to 2.5 s and
0.25 Hz, respectively, to ensure complete deactivation of the
channel. Dose-response relationships were obtained by fitting
experimental data with a Hill equation (Y = Ymax*(1/(1+ (IC50/
x)nH))). Only in those experiments where drug recovery was
complete, a second dose of the drug was tested; in all other cases
each cell was exposed to a single drug concentration.
All data are presented as mean6SEM values. Statistical analysis
was performed with the Student’s t-test for unpaired data. Dose-
Molecular Model of HCN4 Block by Ivabradine
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response curves were compared using the Extra sum-of squares F
test (GraphPad Prism 5). Significance was set at P,0.05.
Ivabradine Docking in hHCN4 Wild-type and Mutant
Channels
Docking of ivabradine to hHCN4 tetramer, both in the closed
and open form, was performed with the program AutoDock4.0
[23] which combines a rapid energy evaluation through pre-
calculated grids of affinity potentials with a variety of search
algorithms to find suitable binding positions for a ligand on a given
protein. When docking, the structure of hHCN4 was kept rigid,
but all the torsional bonds in the ivabradine molecule were set free
to perform flexible docking. Polar hydrogens were added by using
the Hydrogens module in AutoDock Tools (ADT) for hHCN4;
after that, Kollman united atom partial charges were assigned.
Docking was carried out using the Lamarckian genetic algorithm,
applying a default protocol for 100 independent docking runs.
Results were clustered according to the 2.0 A˚ root-mean-square
deviation (RMSD) criterion. The grid maps representing the
proteins in the actual docking process were calculated with
AutoGrid, with a spacing of 0.375 A˚ between the grid points. The
grid size was chosen (and centered) to be sufficiently large to
include the internal channel at the tetrameric hHCN4 interface.
Similar ligand docking procedures were adopted for the hHCN4
mutants Y506A, I510A, and Y506A-I510A, with the channel in
the closed form, and for the F509A mutant with the channel both
in the open and closed form.
Results
Residues Facing the Water-filled Cavity
Previous results have suggested that ivabradine exerts its
blocking action on f/HCN channels by binding to a site within
the aqueous cavity in the inner mouth of the pore [10,11]. A
similar binding location has been proposed for mHCN2 block by
cilobradine [24], a structural analog of ivabradine, and also for
mHCN1/mHCN2 block by ZD7288, a structurally different
molecule [2,24,25].
To identify residues potentially involved in drug binding, we
first explored the spatial orientation of residues facing this inner
cavity by means of an in silico homology 3D model of the pore
region (S5–S6 region) of hHCN4. Homology models were
obtained based on the Streptomyces lividans K+ channel (KcsA) X-
ray structures, both in the closed [12] and in the open
conformation [13] (Fig. 1A). We selected KcsA as a model rather
than Kv1.2 (both are comparably similar to HCN4 in terms of
Figure 1. Homology models of the hHCN4 channel. A: Homology models of the TM1/S5-P-TM2/S6 regions of the hHCN4 channel in the closed
(left) and open form (right), respectively. Only two of the four subunits are shown for clarity. Residues lining the internal cavity are shown in stick
mode and labeled. M508 is also indicated even if it does not point towards the cavity. B: sequence alignment of the TM1/S5-P-TM2/S6 regions of
hHCN4 with the corresponding regions of mHCN1, mHCN2, Streptomyces lividans KcsA, and the mammalian K+ channel Kv1.2. The secondary
structure elements, as defined in the crystal structure of KcsA, are indicated. P is pore, SF is selectivity filter. Residues of HCN channels identical and
similar to those of KcsA and/or Kv1.2 are highlighted by green and yellow boxes, respectively. Residues that face the internal cavity of the hHCN4
channel in the open and closed forms and residues relevant to mHCN2 block by cilobradine [24] and to mHCN1/mHCN2 block by ZD7288 [2,24,25]
are indicated in red bold font.
doi:10.1371/journal.pone.0053132.g001
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sequence alignment) for three main reasons: (i) the KcsA structure
is known in both the closed and open forms, while only the open
structure is available for Kv1.2; (ii) the KcsA structure has been
already used successfully as a model template for the HCN2
channel [24]; (iii) the C-terminal part of the TM2/S6 helix in
Kv1.2 hosts two almost consecutive proline residues (P405, P407)
which confer to the helix a structure divergent from that of KcsA,
where these proline residues are missing (Fig. 1B). Since HCN
sequences do not have proline residues in the TM2/S6 helix, and
prolines usually alter the normal H-bonding pattern of helices, the
choice of KcsA as a model for HCN4 seemed more appropriate.
Both the KcsA-based open and closed models delineate a cavity
lined by residues of the S6 segments and by the lower part of the
pore (P) region, which includes the selectivity filter (SF). More
specifically, in the closed configuration model the inner cavity of
the hHCN4 channel pore lays below the selectivity filter and is
lined by residues L477, C478, A503, Y506, A507, and I510. Note
that the side chains of residues Y506 and I510 are arranged in
a sort of double-layer crown which delimits the floor of this cavity
(Fig. 1A, left). In the open form, the inner cavity is lined by
residues L477, C478, A503, Y506, A507, F509, and I510, and the
diameter of the channel at the cytosolic entrance is ,6.5 A˚ larger
than in the closed structure (distance calculated between I510 side
chains of opposite subunits). In the open conformation the floor of
the inner cavity, even if looser, is still delimited by a double-layer
crown of residues (Y506 and F509, Fig. 1A, right). In Fig. 1B the
sequence alignment of the S5-P-S6 regions of hHCN4 with the
corresponding regions of mHCN1, mHCN2, KcsA, and Kv1.2 is
shown. The alignment reveals that most of the hHCN4 residues
facing the internal cavity (L477, C478, A503, Y506, A507, F509,
and I510, bold red) match those previously reported to be involved
in ZD7288 and cilobradine interactions with mHCN2 (A425,
I432, bold red) [24] and mHCN1 (C347, Y375, M377, F378,
V379, bold red) [2,25]. It is important to note that while residue
M377 of mHCN1 is reported to be potentially involved in the
blocking action of ZD7288 [2], the corresponding residue (M508)
in our models points towards the S5–S6 interface and does not line
the internal cavity in either closed or open forms of the hHCN4
channel (Fig. 1A). Based on the above modeling information, we
generated single mutants by replacing L477, C478, A503, Y506,
A507, M508, F509, and I510 with alanine or, when the native
residue was an alanine, with valine, in order to investigate which of
the potentially interfering residues are involved in ivabradine
binding.
Ivabradine Action on hHCN4 WT and Mutant Channels
All mutations, except L477A were associated with functional
channels when expressed in HEK293 cells and the biophysical
properties are listed in Table S1; as shown in Fig. S1 and Table
S1, the L477A mutant was normally expressed in the plasma
membrane, but did not generate functional currents.
As apparent from the data in Table S1, some of the mutants
underwent significant changes in the voltage dependence of gating
(V1/2 and time constants of activation/deactivation). Since the
blocking action of ivabradine (30 mM) on hHCN4 WT and
mutant currents was evaluated during trains of activating/
deactivating steps (2140/+5 mV), voltages at which all types of
channels were fully open or fully closed, respectively, these
changes did not affect the measurement of mean steady-state
ivabradine block.
The time-courses of current amplitude at 2140 mV during
drug superfusion and sample current traces in control (a) and at
steady-state block (b) are shown in Fig. 2A,B, left and right panels,
respectively. In all cases ivabradine caused a reduction of the
current which accumulated over time until steady-state block was
attained, normally within the first 50–100 s of drug perfusion.
Mean steady-state percent block values were: 88.861.6% (n = 7),
87.663.4% (n = 5), 83.661.9% (n = 5), 33.363.5% (n = 5),
81.963.8 (n = 5), 90.362.0% (n = 6), 41.962.1% (n = 5), and
38.063.1% (n = 4) for WT, C478A, A503V, Y506A, A507V,
M508A, F509A, and I510A channels, respectively. Statistical
analysis revealed that ivabradine blocks C478A, A503V, A507V,
and M508A channels as efficiently as WT hHCN4 channels, but
exerts a significantly less efficient block on Y506A, F509A, and
I510A channels (t-test, P,0.05 vs WT channels). For fuller
comparison, we extended the investigation of ivabradine-induced
block to a wider range of drug concentrations. The resulting dose-
response curves and fitting parameters are shown in Fig. 2C. The
mutant dose-response curves clearly fall into two categories, those
which essentially overlap the hHCN4 WT curve (C478A, A503V,
A507V, and M508A) and those which show a much reduced
(some 20/30-fold lower) sensitivity to the drug (Y506A, F509A,
and I510A). These data indicate that while C478A, A503V,
A507V, and M508A mutations do not affect the efficiency of
hHCN4 channel block by ivabradine, reduced block efficiency is
obtained with the mutations Y506A, F509A, and I510A. This
suggests that residues Y506, F509, and I510 may be involved in
the drug-channel interaction in agreement with the homology
modeling data indicating that the same residues face the internal
surface of hHCN4 pore and form the double layer crown
composing the floor of the cavity in the closed (Y506 and I510)
and open (Y506 and F509) states (Fig. 1A).
Based on these observations, we proceeded to verify the efficacy
of ivabradine block of the double mutants Y506A-I510A and
Y506A-F509A. Both double mutants elicited functional currents.
Properties of the double-mutant currents are provided in Table
S1. The time-courses of current amplitude at 2140 mV during
perfusion with ivabradine 30 mM and sample current traces in
control (a) and at steady-state block (b) are shown in Fig. 3A, as
indicated, for the double-mutant channels investigated. The dose-
response curves of ivabradine block in Fig. 3B show that while the
Y506A and I510A mutations have a cumulative effect
(IC50 = 2213.0 mM) this does not occur for the Y506 and F509A
mutations (IC50 = 43.7 mM). This seems to suggest that a structural
re-arrangement essential to determine ivabradine sensitivity is
common to Y506A and F509A, and that once this has been
rendered by Y506A, further mutating F509 does not provide
a supplemental effect.
We also tested the effect of the triple mutation Y506A-F509A-
I510A and verified that the blocking affinity of ivabradine for this
channel is similar to that of the double mutant Y506A-I510A
(IC50 of 1215.0 and 2213.0 mM, respectively; P.0.05, Fig. 3B);
this further supports the lack of cumulative action of F509A. Thus,
mutation F509A is effective when alone, but not when in
combination with Y506A or Y506A-I510A.
As shown in Fig. 1, F509 points toward the inner cavity only in
the open channel. To gain more insight into the role of F509 we
used a protocol allowing evaluation of ivabradine-induced block of
the F509A mutant specifically in the open channel configuration.
In Fig. 4A sample current traces recorded at steady-state activation
during long (,100 s) hyperpolarizing steps to 2100 mV in the
presence of 3 and 30 mM ivabradine for WT (top) and F509A
(bottom) channels are shown. The full dose-response curves are
shown in Fig. 4B; Hill fitting of experimental data yielded IC50 of
120.7 mM and 91.3 mM for the wild type and F509A mutants,
respectively (not significantly different, P.0.05).
The results in Fig. 4 imply that the F509A mutation does not
modify block developing when channels are in the open state, and
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agree with the hypothesis apparent from the data in Fig. 3 that the
F509A mutation affects the closed channel state, possibly through
the same structural rearrangement associated with the mutation
Y506A.
Ivabradine Docking in WT hHCN4 Channels
The results in Figures 2, 3, and 4 indicate that residues Y506,
F509, and I510 are important determinants of hHCN4 channel
block by ivabradine, with a cumulative action observed for
residues Y506 and I510, but not for residues Y506 and F509, and
a higher efficiency of block predicted for the closed conformation
of channels. The question whether or not these residues directly
interact with ivabradine was addressed by means of an in silico
docking approach using a homology model structure of the
hHCN4 tetrameric pore region. A similar approach was recently
applied to describe the block of HCN2 channels by the drug
ZD7288 [24].
We first analyzed the docking of ivabradine to the hHCN4 WT
channel in its closed state using the estimated Free Energy of
Binding (DGb) as the scoring function. The best clustered docked
models (consisting of 4 models over 100 trials) display an average
DGb of 210.2 kcal/mol, with the bound ivabradine having its
quaternary N atom approximately along the axis of the channel
pore and the benzazepinone and benzocyclobutane moieties
localized in two of the four hydrophobic pockets lined by L477,
C478, A503, and Y506 from different subunits (Fig. 5A). The
docked ivabra\dine molecule is stabilized by several van der Waals
and hydrophobic interactions with at least one of its heterocyclic
moieties (both in the best ivabradine docking pose) making
stacking interactions with the Y506 side-chains which build the
floor of the cavity (Fig. 5A); only one ivabradine molecule is hosted
Figure 2. Ivabradine-induced block of WT and mutant hHCN4 channels. A,B: time-courses of current amplitudes (left panels) and sample
current traces (right panels: a, control; b, steady-state block) recorded at 2140 mV before, during, and after superfusion with 30 mM ivabradine
(horizontal bars). Horizontal bars in right panels: 150 ms. C: Dose-response relations of ivabradine block of WT and mutant channels. Fitting with the
Hill equation (curves) yielded half-block concentrations (IC50) of 2.1, 3.1, 3.6, 57.7, 3.7, 1.9, 44.0, 47.7 mM and Hill coefficients (nH) of 0.74, 0.84, 0.72,
1.02, 0.75, 0.77, 0.73, 0.83 for WT, C478A, A503V, Y506A, A507V, M508A, F509A, and I510A channels, respectively. Dose-response relations for Y506A,
F509A, and I510A curves are significantly different from WT (P,0.05).
doi:10.1371/journal.pone.0053132.g002
Molecular Model of HCN4 Block by Ivabradine
PLOS ONE | www.plosone.org 5 January 2013 | Volume 8 | Issue 1 | e53132
in the cavity. Note that the average distance of the ivabradine
quaternary N atom from the innermost permeating ion binding
position (lowest dot in Fig. 5A) is 2.6 A˚, calculated over the 4
models of the best docking cluster; this distance reduces to only
1.5 A˚ for the best-docked pose (DGb =210.5 kcal/mol) within the
best docking cluster (Fig. 5A). In this latter case the positively
charged ivabradine quaternary N atom lies at a distance of 3.1–
3.7 A˚ from each of the four carbonyl oxygen atoms of C478 of the
selectivity filter, thus suggesting that the best stabilization of the
bound ivabradine to the tetrameric closed channel may include
additional H-bonds during the dynamic ligand-receptor interac-
tions.
An important observation emerging from the docking analysis is
the structural role played by residues Y506 and I510. In the
tetrameric hHCN4 closed channel model, the four Y506 side-
chains point to the interior of the channel and form the floor of the
cavity hosting ivabradine (Figs. 1A left, 5A). Furthermore, I510
residues fall right below Y506 residues, and by means of
hydrophobic interactions may stabilize the orientation of the
Y506 side-chains (Figs. 1A left, 5A).
We then analyzed ivabradine docking to the hHCN4 WT
channel in the open form. As pointed out in Fig. 1A, right, when
the channel is open, the internal cavity takes a more relaxed and
enlarged conformation. The best clustered ivabradine docked
models (2 models over 100 trials) showed an average
DGb =28.04 kcal/mol, a value smaller than that estimated for
the closed WT hHCN4 channel (DGb =210.2 kcal/mol). In the
open channel, docked ivabradine molecules adopt a bent confor-
mation, with the benzazepinone and benzocyclobutane moieties
almost parallel to each other and stabilized by stacking interactions
to the aromatic side-chains of Y506 and F509 (Fig. 5B). The
ivabradine quaternary N atom is now positioned far below the
permeating ion binding site (distance of 8.5 A˚ calculated over the 2
docking solutions of the best cluster), in the region of the channel
lined by the F509 side-chains.
Ivabradine Docking in hHCN4 Mutant Channels
To verify if modeling is able to explain changes in block
efficiency as those found in electrophysiology experiments with
mutant Y506A and I510A channels (Figures 2 and 3), we
Figure 3. Block of double (Y506A-I510A and Y506A-F509A) and triple (Y506A-F509A-I510A) mutant channels by ivabradine. A, top,
sample currents recorded at 2140 mV from the two double mutant channels Y506A-I510A and Y506A-F509A in control (a) and after steady-state
block by ivabradine 30 mM (b); A, bottom, time course of currents at2140 mV during ivabradine perfusion. B: dose-response relations; Hill fitting (full
lines) yielded IC50, nH values of 2213.0 mM, 0.7, 42.5 mM, 0.8, and 1215.0 mM and 0.68 for Y506A-I510A, Y506A-F509A, and Y506A-F509A-I510A
respectively. Hill fitting of WT and Y506A block from Fig. 2 also drawn for comparison (dotted lines). The two double-mutant curves are significantly
different between themselves and from that of WT channels (P,0.05); the Y506A-I510A and the Y506A-F509A-I510A curves are not significantly
different (P,0.05).
doi:10.1371/journal.pone.0053132.g003
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performed additional modeling and docking calculations for the
two single mutants Y506A and I510A and for the double mutant
Y506A-I510A (Fig. 6). Inspection of the Y506A mutant model
structure indicates that mutation increases the volume of the
docking cavity (Fig. 6A); the floor of the ivabradine docking cavity
is now built by the I510 side-chains. The best clustered docking
models for Y506A mutant indicate for ivabradine a bent
conformation with the benzazepinone and benzocyclobutane
moieties almost orthogonal to each other, with one moiety located
in the pocket lined by C478, A503, and the mutated A506, and the
other moiety fitting most of the volume which in the hHCN4 WT
channel is occupied by the Y506 side-chains, close to I510 side-
chains. The best docking cluster (3 models over 100 trials) for the
Y506A mutant, with the channel in the closed form, show an
average DGb =28.02 kcal/mol, a value smaller than that
estimated for the closed WT hHCN4 channel
(DGb =210.2 kcal/mol). This indicates that the lack of the
Y506 side-chain decreases the stabilization of the bound ligand
and allows for a different spatial position of ivabradine, with its
quaternary N atom displaced from the center of the pore and
more distant from the lowermost permeating ion binding site
(4.3 A˚ averaged over the 3 models of the best solution cluster).
When we modelled the I510A mutant, we noticed that the loss
of the hydrophobic interactions between Y506 and I510 side-
chains allows the Y506 side-chain of each subunit of the tetrameric
channel to re-orient away from the centre of the pore (Fig. 6B).
Indeed, the best I510A mutant model shows that now each Y506
side-chain is located in a subunit-subunit interface, in a cavity
lined by L447, G502, and F509 from one subunit, and I510, A503,
and T504 from the adjacent subunit. Such new orientation of
Y506 determines a structure of the lower part of the channel and
a docking behaviour of ivabradine similar to that found in the
Y506A mutant (Fig. 6A, B), with the best docking cluster (3 models
over 100 trials) having an average DGb =28.29 kcal/mol. This
agrees with the evidence above that both the Y506A and I510A
single mutants are characterized by a much lower affinity to
ivabradine than both the WT and any other single mutant
hHCN4 channel (Fig. 2).
Modelling of the Y506A-I510A double mutant shows that the
double crown side-chain layer making the floor of the internal
cavity in WT hHCN4 closed channel is now completely removed,
which allows for an enlarged volume of the docking cavity at the
cytosolic side of the channel (Fig. 6C). As a consequence, the
docked ivabradine molecule can span a wider number of
conformations, with the benzazepinone and benzocyclobutane
moieties now fitting in the cavity lined by C478, A503, and A506
side-chains and in the cavity below lined by A503, A506, and
A510, respectively. The best docking cluster for the double mutant
(3 models over 100 trials) has an average DGb =26.7 kcal/mol,
much smaller than those of the hHCN4 WT and of Y506A and
I510A single mutants, with the best docking-pose of ivabradine in
a bent conformation reminiscent of that found in the Y506A and
I510A mutants (Figs. 6A,B,C).
We then further analyzed the role of the F509 residue by means
of modeling and docking experiments with the F509A mutant in
both the open and closed forms. The open form of the F509A
mutant channel shows a more enlarged conformation of the lower
part of the channel cavity when compared to that of the WT
hHCN4 (Fig. 6D). The best docking cluster (3 models over 100
trials) shows an average DGb =27.16 kcal/mol. In the F509A
open channel mutant the docked ivabradine molecule adopts an
elongated conformation along the channel axis with the
benzazepinone and benzocyclobutane moieties almost orthogonal
to each other, the first hosted in the pocket lined by L477, C478,
A503, and Y506 and the second in the pocked lined by Y506,
A509 and I510 (Fig. 6D). DGb values calculated for the open WT
and F509A channels are comparable (28.04 vs 27.16 kcal/mol),
which agrees with the electrophysiological evidence that the
residue F509 is not relevant to the open channel block (Fig. 4).
Interestingly, when we modelled the F509A mutant in the hHCN4
closed form, we observed that the absence of the F509 side-chain
promotes an overall rearrangement of the surrounding structure.
Indeed, as shown in Fig. 6E and Fig. S2, the removal of the F509
side-chain makes room for the Y506 side-chain of each subunit,
which may thus move from the centre of the pore towards the
subunit-subunit interface as seen in the I510A mutant (Figs. 6B).
For the best ivabradine cluster results (6 models over 100 trials) the
average DGb =28.95 kcal/mol is similar to that found for the
I510A mutant (DGb =28.29 kcal/mol) and smaller than that
found for WT hHCN4 (DGb =210.2 kcal/mol).
Modeling thus provides an explanation for the block data
obtained with the F509A mutation (Figs. 1 to 4) and confirms the
hypothesis that the reduction of block sensitivity for this mutant is
an indirect effect associated with the displacement of residue
Y506.
Figure 4. Ivabradine block of WT and F509A channels in the
open state. A, representative traces showing the action of ivabradine
(3 and 30 mM) on the current recorded from WT and F509A channels
during a long (100 s) step to 2100 mV. B, dose-response relations for
ivabradine block measured as in A. Hill fitting resulted in IC50, nH values
of 120.7 mM, 0.5 and 91.3 mM, 0.5 for WT (filled circles) and F509A
channels (open circles), respectively (non-significantly different,
P.0.05).
doi:10.1371/journal.pone.0053132.g004
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Discussion
The relevance of the If current to cardiac pacemaker generation
and modulation of rate has been documented both in experimen-
tal animals and in humans where it represents an important
pharmacological target [26]. A detailed understanding of drug-
channel interaction is therefore essential in the perspective of
improving HCN isoform-specific selectivity of block, particularly
since differential isoform distribution in heart and brain may
underlie isoform-dependent pathologies including for example
arrhythmias, epilepsy, motor learning defects, pain transmission
[7,8,27,28]. We therefore sought to investigate details of
ivabradine-induced block by identifying residues involved in the
binding of ivabradine to HCN4, the HCN isoform most highly
expressed in the sinoatrial node. Previous studies have suggested
that the cytoplasmic side of HCN channels is composed of a water-
filled cavity guarded by an intracellular activation gate and that
the binding site for HCN blocker drugs such as ZD7288,
ivabradine, and cilobradine is located within this central cavity
[2,3,10,11,24,25]. Although these studies have indicated the
involvement of some specific residues, they did not provide an
integrated and detailed description of the structural arrangement
of the cavities in the channel open and closed states, and how this
arrangement affects ivabradine block.
The homology models shown in Fig. 1A aim to fill this gap by
providing structural information on the spatial organization of
residues in the S6 domain and in the S5–S6 linker that line the
internal cavity in both open (L477, C478, A503, Y506, A507,
F509, and I510) and closed (L477, C478, A503, Y506, A507, and
I510) channel states. A similar 3D modeling approach, has been
previously proposed for mHCN2 [24], though limited to the open
state of the channel. According to Cheng et al.’s study [24],
mHCN2 residues A425 and I432 (structurally homologus to A503
and I510 of hHCN4) face the internal cavity of channels, in
agreement with our data.
As shown by our previous studies [10,11], the mechanism of
action of ivabradine block is quite complex. The drug can only
access its binding site, located in the internal channel cavity, when
f/HCN4 channels are in the open state. Also, block is current-
Figure 5. Detailed stereo view of the ivabradine docking in the hHCN4 WT channel. Stereo view of the interior of the WT hHCN4 channel
in its closed (A) and open (B) form with the best-docked pose of ivabradine shown in magenta. The S5-P-S6 regions of the four hHCN4 subunits are
shown as ribbon in green yellow, orange and pale blue, respectively. Side-chains of residues interacting with the ivabradine molecule are shown in
stick representation in both panels. For the closed state only, the main-chain atoms of C478 are shown since the carbonyl oxygen atoms may form
additional H-bonds with ivabradine. I510 is also shown in the channel closed form, though this residue does not interact directly with ivabradine.
Black spheres indicate positions corresponding to K+ ion bound in pore of the KcsA crystal structure [12]. For clarity only residues of one subunit are
labeled and L477 of the pale blue subunit is omitted.
doi:10.1371/journal.pone.0053132.g005
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dependent since the inward current flow at hyperpolarized
potentials removes block (kick-off), while depolarization favors
block development (kick-in); this mechanism is responsible for the
use-dependence of ivabradine. In addition, the property of
current-dependence suggests that the ionic flow through the
channel pore proceeds according to a multi-ion single file
permeation model, and that the charged nitrogen of ivabradine
competes with permeating Na+/K+ ions at one of the coordination
sites along the permeation pathway, most likely the innermost one
[10]. Since the present interpretation of mechanisms underlying
the interaction between ivabradine and HCN channels relies
essentially only on electrophysiological data, we used a combina-
tion of alanine-scanning mutagenesis and 3D-modeling and
docking in the attempt to resolve the molecular basis of channel
block.
The first important information yielded by the modeling
approach is the indication that when the channel is in the open
state, the smallest diameter of the internal mouth of the cavity is of
about 11 A˚ (calculated between F509 side-chains of opposite
subunits), which is enough to allow ivabradine to access the cavity
in a dynamic structural context. On the contrary, when the
channel is in the closed state, ivabradine cannot enter since the
smallest diameter of the internal cavity is about 4–5 A˚ (calculated
either between the T514 or between the I510 side-chains of
opposite subunits). These data thus provide an explanation for the
known "open channel" block property of ivabradine [10] and for
the "trapping" of blocking molecules within the channel in the
closed state, a property described also for the block of mHCN1 by
ZD7288 [2–6].
Electrophysiological analysis of mutant block by ivabradine
indicate that the residues forming the floor of the closed cavity
(Y506 and I510, Fig. 1A) are major determinants of ivabradine
block measured during activation/deactivation protocols (Figures 2
and 3). These data indeed show that block is similarly reduced in
Y506A and I510A mutant channels (Fig. 2; IC50 = 57.7 and
47.7 mM, respectively), and is further strongly reduced in the
double mutant Y506A-I510A (Fig. 3, IC50 = 2213.0 mM). The
structural position occupied by residues Y506 and I510 in hHCN4
appears to be critical for drug binding also in hERG channels,
since the corresponding aminoacids (Y652 and F656) have been
identified as critical elements for the interaction with several
structurally unrelated drugs [29–31]. A molecular rationale to
interpret the block data of HCN4 channels can be obtained from
3D-modeling. As shown in Fig. 5, the ‘‘best’’ pose of drug
molecules within the channel differs substantially in closed and
open channels. In the closed state, the position occupied by
ivabradine is proximal to the internal pore end and is stabilized by
a floor formed by the side-chains of residues Y506 and supported
by I510 residues, representing the inner boundary of the channel
cavity. In the open channel state the floor of the cavity is partly
disassembled, and as a consequence the cavity is wider and
ivabradine finds a stable binding site in a position farther away
from the pore; given the larger opening of the inner cavity (about
11 A˚), ivabradine molecules are not trapped anymore and move
easily across it.
As discussed above, our simulations highlight a significant re-
shaping of the docking cavity when channels change from the
open to the closed state. As well as acquiring a more pore-
proximal position relative to the open state, in the closed state drug
molecules modify their orientation such that the quaternary N
atom moves from a more peripheral to a more central position
relative to the pore axis. In closed channels, the position acquired
by the N-atom is sufficiently close to the lowermost of the binding
sites of permeating ions (1.5 A˚) to antagonize their binding. This
provides a satisfactory explanation of the property of ‘‘current
dependence’’ of block previously described [10]. 3D-docking
model analysis indicates that the values of the DGb of ivabradine
binding to the two mutant Y506A and I510A closed channels are
similar (28.02 kcal/mol and 28.29 kcal/mol, respectively) and
are both smaller than that for the WT closed channels
(210.2 kcal/mol). This agrees with the experimental evidence
presented in Fig. 2 that block is similarly reduced for Y506A and
I510A relative to WT, and further stresses the evidence that
modeling and electrophysiological data converge in the interpre-
tation of block features.
Docking analysis of ivabradine in WT closed channel (Fig. 5A)
shows that the drug interacts directly with Y506 but not with I510.
However I510 residues lie beneath the Y506 side chains and their
interactions maintain the orientation of both residues toward the
centre of the cavity. In the I510A mutant channel, these
interactions are lost and, as a consequence, the Y506 side-chains
can now change their orientation in a way which decreases the
stabilization of the bound ligand (Fig. 6B).
Results obtained with the double mutant Y506A-I510A, where
according to 3D modeling the integrity of the floor of the cavity is
disrupted in the closed configuration (Fig. 1), concur to indicate
that residues Y506 and I510 are major determinants of block
efficiency (Fig. 3, 6C). Consistent with block data, the DGb is
smaller for the double mutant (26.70 kcal/mol) than for either of
the two single mutant channels.
As for the open channel, the experiments with double and triple
mutants (Fig. 3) reveal that the role of the floor of the cavity,
formed mainly by residues Y506A and F509A, is less critical.
While block of the single F509A mutant is reduced, indicating
a role for this residue in block determination, data in Fig. 3 and
Fig. 4 rule out a direct contribution. According to the analysis of
ivabradine docking to F509A channels (Fig. 6D, E), this can be
explained by assuming that the F509 side-chain exerts a spatial
constraint on the orientation of Y506, and its removal causes
a rotation of the Y506 side-chain, an effect able to destabilize
ivabradine binding. This is indeed verified when comparing the
orientation of Y506 side-chains in the F509A mutant channel (Fig.
S2).
Comparison with Previous Studies
Our hHCN4 model can be compared with previous studies of
other HCN channels based on homology modeling, scanning
accessibility and/or drug interaction experiments.
Investigation of spHCN and mHCN1 channel block by
ZD7288 has shown that residues homologous to hHCN4 Y506,
M508 and I510 are accessible to drug block and therefore face the
internal cavity of channels [2]. These results agree with our finding
that Y506 and I510 face the pore, while in our model M508 does
not line the internal cavity but rather points towards the S5–S6
Figure 6. Detailed stereo view of the ivabradine docking to hHCN4 mutant channels. A,B,C: stereo views of the interior of hHCN4 mutants
Y506A (A), I510A (B), and Y506A-I510A (C) in the closed form. D, E: stereo views of the interior of the F509A mutant in the open (D) and closed (E)
form. Side-chains of residues relevant to ivabradine binding are shown as ball-and-stick in all panels. In all mutant models the best pose of the
docked ivabradine is shown in magenta, while the S5-P-S6 regions of the four hHCN4 subunits are shown as ribbon in grey, yellow, orange and pale
blue, respectively. For clarity, residues have been labelled only in one hHCN4 subunit, with mutated residues indicated in bold characters.
doi:10.1371/journal.pone.0053132.g006
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interface. It is interesting to note, however, that Chan et al. [25]
recently found that mHCN1 M377, homologous of hHCN4
M508, does not face the cytoplasmic side of the pore. The same
authors [25] also reported that mHCN1 residues homologous to
hHCN4 C478, C505, F509 and I510 face the internal cavity in
agreement with our data.
mHCN2 residues homologous to hHCN4 A503 and I510 also
face the internal cavity as in our model according to Cheng et al.
[24]. Our hHCN4 model is also consistent with cysteine-scanning
mutagenesis experiments showing that spHCN C428 (homologous
to hHCN4 C478) faces the cytoplasmic side of the channel pore,
while spHCN K433 (homologous to hHCN4 R483) faces the
extracellular vestibule [32].
Further investigation by cysteine-scanning mutagenesis [3,33]
has shown that spHCN residue Q468, corresponding to hHCN4
Q518, is accessible in the closed channel state, while T464,
corresponding to T514, is not. These results suggest that the
narrowest region of the crossing bundle lies in the vicinity of the
end of S6. Giorgetti et al. [4] identify spHCN Q468 as the position
of narrowest opening of the spHCN crossing bundle in the closed
channel state (their Fig. 8). Although we have not performed
accessibility experiments, our homology 3D model predicts that
the narrowest region of the channel (in the closed state) is located
close to T514 (thus slightly upstream of that reported for spHCN
channels) with Q518 protecting T514 from the solvent at the
cytosolic side. In our model Q518 is therefore accessible even in
the closed channel state, while T514 is not.
Giorgetti et al. [4] used the crystal of the MthK channel as
a template to model the open spHCN channel. Since this model
failed to explain experimental results with cysteine-scanning and
Cd2+ block experiments [3,33], an additional constraint was
applied by the authors to reorient the C-terminus of the S6 helix
which reduced the bending of helix S6 of about 18u relative to
MthK. More recently the open form of the KcsA channel has been
published [13], and we took advantage of this knowledge to model
the open form of hHCN4. In our model we did not impose any
additional rotational constraint, and as a result the orientation of
the C-terminal part of the helix S6 in hHCN4 is about 10u less
kinked (at G502) than the MthK S6, a bending intermediate
between those of the spHCN model and the MthK crystal
structure.
Conclusions
Our data indicate that the ivabradine binding site is located
within the inner cavity of HCN4 channels, where the bound
ivabradine is stabilized by several van der Waals and hydrophobic
interactions. Although this happens both in the closed and in the
open channel forms (Fig. 5), the drug binding mode differs
substantially in the two channel states. In particular, the position
acquired by the ivabradine N-atom in the closed channel is
sufficiently close to the lowermost permeating ion binding site to
antagonize their binding, in agreement with current-dependent
block. According to our results, the major determinant of
ivabradine binding to the channel is the structural integrity of
the floor of the cavity in the closed channel, represented by the
double crown built by residues Y506 and I510 in the tetrameric
assembly.
Our data indicate that the affinity of ivabradine binding to the
blocking site is higher in the closed than in the open state of the
channel. This feature does not contrast with the property of "open
channel block", since it simply reflects the need of channels to be
open for drug molecules to reach their binding site. In fact, this
functional property corresponds to our model predictions whereby
the drug cannot reach, nor leave, the docking site when the
channel is in the closed state.
Thus, the block mechanism can be summarized as follows: 1)
ivabradine needs an open channel to access its binding site; 2)
open channels, depolarization, and outward current flow favour
access to the blocking site by means of a "current-dependent"
mechanism; 3) when the channel is closed, the drug molecule is
"trapped" in the cavity and cannot be displaced by either inward
or outward flow; trapping depends strongly upon side chains of the
Y506 and I510 residues.
Trapping of blocking molecules has been described already for
the binding of ZD7288 to mHCN2 channels [24]. Although the
mechanisms of block of ZD7288 on mHCN2 and of ivabradine on
hHCN4 are clearly not identical, some specific similarities exist.
For example, similar effects are observed when the structurally
homologous residues I510 (hHCN4) and I432 (mHCN2) are
replaced by alanine. On the other hand, also important differences
exist. For example, Y506 (hHCN4) is involved in determining the
steady-state hHCN4 block by ivabradine, but the corresponding
mHCN2 Y428 has no effect on steady-state mHCN2 block by
ZD7288. Overall these data suggest that while the blocking sites of
both drugs reside in the channel cavity, the detailed molecular
interactions with surrounding residues differ substantially in
hHCN4 and mHCN2. This agrees with the notion that ZD7288
block is not current-dependent [10].
Supporting Information
Figure S1 Membrane expression of L477A mutant channels.
Videoconfocal images of HEK293 cells transfected with hHCN4
WT (top panels) and L477A mutant cDNA (bottom panels), and
immunolabelled with anti hHCN4 antibodies (red). In both cases
a strong membrane-associated fluorescence is detected, indicating
that the protein localizes to the membrane. The lack of current
expression in the L477A mutant channel (see Table S1) may
therefore indicate that substitution of L477 functionally impairs
the ability of the channel to carry the current. Each image
represents the scanning of a single video-confocal section. Nuclei
labeled with DAPI.
(TIF)
Figure S2 The Y506 side chain in F509A is rotated relative to
wild-type channels. View of the interior of the hHCN4 wt (gray)
and F509A mutant channels (orange) in the closed form. Side-
chains of Y506 and F509 in the wt, and of Y506 and A509 in the
mutant F509A channels are shown as ball-and-stick. In magenta is
the best pose of docked ivabradine for the F509A mutant.
(TIF)
Materials and Methods S1 Methods for immunolabeling.
(DOC)
Table S1 Biophysical properties of hHCN4 WT and mutant
channels expressed in HEK293 cells. V1/2, voltage of half-
maximal activation; s, slope factor of activation curve; tact,
activation time constant measured at 2140 mV (single exponen-
tial fit); tdeact, deactivation time constant measured at +5 mV
(single exponential fit); *P,0.05 vs WT channels.
(DOC)
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